Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

Charts and graphs v1

No description

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Charts and graphs v1

Total Number of Companies:
30%

Private
70%

Public
30%

Public
70%

Private
134
CT companies
289
Products
111
CT companies
154
Products
134 CT Companies are Developing 289 Products
111 GT Companies Developing 154 Products
83
N. America
30
Europe
17
Asia
4
Australia
61
N. America
32
Europe
13
Asia
2
Australia
3
S. America
273
Tested
154
Tested
273 of these products are being tested in preclinical and clinical trials
154 of these products are being tested in preclinical and clinical trials
Preclinical
Oncology
CNS
Cardiovascular
42
Ophthalmology
42
18
11
Oncology
CNS
Endocrine/
Metabolic
25
Ophthalmology
16
16
17
Phase 1
Phase 2
Phase 3
Marketed
Oncology
CNS
Cardiovascular
23
7
11
Oncology
CNS
Musculoskeletal
4
4
3
Cardiovascular
Oncology
CNS
Cardiovascular
Dermatology
14
20
10
Oncology
Cardiovascular
Hematology
9
Ophthalmology
5
5
5
Oncology
CNS
Cardiovascular
11
14
5
Oncology
3
Dermatology
4
Dermatology
2
Cardiovascular
3
Public vs Private
Gene therapy: 134
Cell therapy: 111
20
49
Oncology
Dermatology
Musculoskeletal
8
5
12
Inflammation/
immunology
5
Endocrine/
Metabolic
Glybera
Full transcript